Cargando…

Pharmacophore modeling for identification of anti-IGF-1R drugs and in-vitro validation of fulvestrant as a potential inhibitor

Insulin-like growth factor 1 receptor (IGF-1R) is an important therapeutic target for breast cancer treatment. The alteration in the IGF-1R associated signaling network due to various genetic and environmental factors leads the system towards metastasis. The pharmacophore modeling and logical approa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khalid, Samra, Hanif, Rumeza, Jabeen, Ishrat, Mansoor, Qaisar, Ismail, Muhammad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5963753/ https://www.ncbi.nlm.nih.gov/pubmed/29787591 http://dx.doi.org/10.1371/journal.pone.0196312

Ejemplares similares

Association of rs1801157 single nucleotide polymorphism of CXCL12 gene in breast cancer in Pakistan and in-silico expression analysis of CXCL12–CXCR4 associated biological regulatory network
por: Khalid, Samra, et al.
Publicado: (2017)

Combined Pharmacophore and Grid-Independent Molecular Descriptors (GRIND) Analysis to Probe 3D Features of Inositol 1,4,5-Trisphosphate Receptor (IP(3)R) Inhibitors in Cancer
por: Ismatullah, Humaira, et al.
Publicado: (2021)

Formal modeling and analysis of ER-α associated Biological Regulatory Network in breast cancer
por: Khalid, Samra, et al.
Publicado: (2016)

Retrospective Evaluation of Fulvestrant Efficacy and Clinical Results in Patients Using Fulvestrant
por: Kut, Engin, et al.
Publicado: (2023)

Fulvestrant: pharmacokinetics and pharmacology
por: Robertson, J F R, et al.
Publicado: (2004)

Search for the Pharmacophore of Histone Deacetylase Inhibitors Using Pharmacophore Query and Docking Study
por: Haji Agha Bozorgi, Atefeh, et al.
Publicado: (2014)

Identification of novel anti-amoebic pharmacophores from kinase inhibitor chemotypes
por: Ferrins, Lori, et al.
Publicado: (2023)

Silencing MED1 Sensitizes Breast Cancer Cells to Pure Anti-Estrogen Fulvestrant In Vitro and In Vivo
por: Zhang, Lijiang, et al.
Publicado: (2013)

Economic Evaluation for Palbociclib Plus Fulvestrant vs Ribociclib Plus Fulvestrant and Abemaciclib Plus Fulvestrant in Endocrine-Resistant Advanced or Metastatic Breast Cancer in Italy
por: Colombo, Giorgio Lorenzo, et al.
Publicado: (2023)

Corrigendum: Identification of novel anti-amoebic pharmacophores from kinase inhibitor chemotypes
por: Ferrins, Lori, et al.
Publicado: (2023)

Anti-tumor efficacy of fulvestrant in estrogen receptor positive gastric cancer
por: Yi, Jun Ho, et al.
Publicado: (2014)

Pharmacophore and Virtual Screening of JAK3 inhibitors
por: Rajeswari, Murugesan, et al.
Publicado: (2014)

Pharmacophoric Site Identification and Inhibitor Design for Autotaxin
por: Lee, Myeong Hwi, et al.
Publicado: (2019)

Glioblastoma Multiforme: Probing Solutions to Systemic Toxicity towards High-Dose Chemotherapy and Inflammatory Influence in Resistance against Temozolomide
por: Nasir, Sadia, et al.
Publicado: (2023)

Fulvestrant-induced toxic epidermal necrolysis
por: Morales-Conde, Macarena, et al.
Publicado: (2019)

A Review of Fulvestrant in Breast Cancer
por: Nathan, Mark R., et al.
Publicado: (2017)

Pharmacophore-Based Virtual Screening and Experimental Validation of Pyrazolone-Derived Inhibitors toward Janus Kinases
por: Sanachai, Kamonpan, et al.
Publicado: (2022)

Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial
por: Schmid, Peter, et al.
Publicado: (2019)

QPHAR: quantitative pharmacophore activity relationship: method and validation
por: Kohlbacher, Stefan M., et al.
Publicado: (2021)

Pharmacophore Models and Pharmacophore-Based Virtual Screening: Concepts and Applications Exemplified on Hydroxysteroid Dehydrogenases
por: Kaserer, Teresa, et al.
Publicado: (2015)

Revisiting Fulvestrant Dosing in Uncertain Economic Times
por: Patel, Amol, et al.
Publicado: (2021)

Association between breast cancer and tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) gene 1595C/T SNP in a Pakistani population
por: Rehman, Saima F., et al.
Publicado: (2015)

High Expression Levels of Total IGF-1R and Sensitivity of NSCLC Cells In Vitro to an Anti-IGF-1R Antibody (R1507)
por: Gong, Yixuan, et al.
Publicado: (2009)

Development and Validation of a Gene Expression Score That Predicts Response to Fulvestrant in Breast Cancer Patients
por: Knudsen, Steen, et al.
Publicado: (2014)

Discovery of anti-MERS-CoV small covalent inhibitors through pharmacophore modeling, covalent docking and molecular dynamics simulation
por: Alamri, Mubarak A., et al.
Publicado: (2021)

Pharmacophore elucidation and molecular docking studies on phosphodiesterase-5 inhibitors
por: Radwan, Awwad Abdoh
Publicado: (2015)

IGF1R activation and the in vitro antiproliferative efficacy of IGF1R inhibitor are inversely correlated with IGFBP5 expression in bladder cancer
por: Neuzillet, Yann, et al.
Publicado: (2017)

A new strategy based on pharmacophore-based virtual screening in adenosine deaminase inhibitors detection and in-vitro study
por: Bazl, Roya, et al.
Publicado: (2012)

Discovery of Small Molecules as Membrane-Bound Catechol-O-methyltransferase Inhibitors with Interest in Parkinson’s Disease: Pharmacophore Modeling, Molecular Docking and In Vitro Experimental Validation Studies
por: Cruz-Vicente, Pedro, et al.
Publicado: (2021)

Pharmacophore Oriented MP2 Characterization of Charge Distribution for Anti-SARS-CoV-2 Inhibitor Nirmatrelvir
por: Liu, Yuemin, et al.
Publicado: (2023)

Linkage disequilibrium block single-nucleotide polymorphisms in FTO alpha ketoglutarate dependent dioxygenase gene inference with breast cancer and Type II diabetes in Pakistani female population
por: Mansoor, Qaisar, et al.
Publicado: (2023)

Fulvestrant and the sequential endocrine cascade for advanced breast cancer
por: Johnston, S
Publicado: (2004)

Oestradiol measurement during fulvestrant treatment for breast cancer
por: Owen, Laura J., et al.
Publicado: (2019)

Abemaciclib/fulvestrant: Leucopenia and Covid-19: case report
Publicado: (2020)

Fulvestrant-Big Mac Index: Defining Inequality in Oncology
por: O'Reilly, David, et al.
Publicado: (2021)

Topological pharmacophores: pros & cons of QSARs based on 2D pharmacophore fingerprints
por: Horvath, D
Publicado: (2008)

Ligand-Based Pharmacophore Modeling Using Novel 3D Pharmacophore Signatures
por: Kutlushina, Alina, et al.
Publicado: (2018)

Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrant
por: Kümler, Iben, et al.
Publicado: (2016)

Fulvestrant in Combination with CDK4/6 Inhibitors for HER2- Metastatic Breast Cancers: Current Perspectives
por: Iorfida, Monica, et al.
Publicado: (2020)

Dynamic and Multi-Pharmacophore Modeling for Designing Polo-Box Domain Inhibitors
por: Sakkiah, Sugunadevi, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_m9qd9snk9lr81li9a9q532u3nh